Review the pharmacology of PARP inhibitors and their use in BRCA-mutated malignancies including breast, ovarian, fallopian tube, and primary peritoneal cancers.
U.S. Pharmacist
Original Article: Role of PARP Inhibitors in BRCA-Related Malignancies